PMGC Holdings (ELAB) Current Assets (2022 - 2026)
PMGC Holdings (ELAB) posted Current Assets of $16.4 million for Q1 2026, up 138.48% sequentially from $6.9 million in Q4 2025, and up 140.41% YoY from $6.8 million in Q1 2025.
PMGC Holdings (ELAB) Current Assets (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Current Assets for 5 years, with the latest figure at $16.4 million in Q1 2026.
- Quarterly Current Assets rose 140.41% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.4 million (up 140.41% YoY) and the FY2025 annual result came in at $6.9 million, up 13.56% from the prior year.
- Current Assets rose to $16.4 million in Q1 2026 per ELAB's latest filing, from $6.9 million in the prior quarter.
- Over five years, Current Assets peaked at $1.3 billion in Q3 2023 and troughed at $1.6 million in Q4 2022.
- A 5-year average of $112.5 million and a median of $6.8 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets tumbled 99.36% in 2024, then soared 259.55% in 2025.
- Over 5 years, Current Assets stood at $1.6 million in 2022, then surged by 217.11% to $4.9 million in 2023, then increased by 23.0% to $6.1 million in 2024, then advanced by 13.56% to $6.9 million in 2025, then jumped by 138.48% to $16.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $16.4 million, $6.9 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | 20.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.39 Mn |
| Dec 31, 2025 | 6.87 Mn |
| Sep 30, 2025 | 9.77 Mn |
| Jun 30, 2025 | 7.30 Mn |
| Mar 31, 2025 | 6.82 Mn |
| Dec 31, 2024 | 6.05 Mn |
| Sep 30, 2024 | 8.23 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 4.92 Mn |
| Sep 30, 2023 | 1.28 Bn |
| Dec 31, 2022 | 1.55 Mn |